Lifecore Biomedical, Inc. (LFCR)

Lifecore Biomedical's stock price has been volatile in the past six months. Shares plunged over 33% following the Q4 2025 earnings report due to delayed volume expectations from key customers. Q1 2026 financial results showed a 34% year-over-year revenue decline and a net loss, leading to a moderate negative market reaction. Despite declines, Lifecore reaffirmed its 2026 revenue and adjusted EBITDA guidance and signed three new commercial site transfer programs in Q1 2026. Over the last year, LFCR shares have hit a 52-week high of $8.98 and a 52-week low of $3.63.

While specific seasonal fluctuations are not detailed, Lifecore operates in the CDMO market, which is experiencing high demand for specialized services like aseptic fill-finish and hyaluronic acid (HA) production. The company anticipates modest revenue growth in 2027, with significant growth continuing into 2028, driven by the expansion of existing customer programs and the commercialization of its late-stage pipeline, suggesting a generally increasing demand trend rather than distinct seasonal patterns.

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) in the healthcare sector, specializing in sterile injectable pharmaceutical products and pharmaceutical-grade sodium hyaluronate (HA). The company offers product development services and was formerly known as Landec Corporation, changing its name in November 2022 to focus on its life sciences business.

Lifecore Biomedical, Inc. is headquartered in Chaska, Minnesota, United States, and serves customers in the United States, Belgium, the Netherlands, and internationally. Its campus in the Twin Cities area supports manufacturing operations, packaging, warehousing, distribution, and quality control.

Lifecore Biomedical has been strengthening its brand reputation as a trusted U.S.-based CDMO partner, known for technical excellence, quality, and reliability in sterile injectables. However, a class-action lawsuit was filed in August 2024, alleging that the company misled investors regarding its internal controls over financial reporting, which could have negatively impacted investor confidence and the company's overall brand image.

Lifecore Biomedical, Inc. has a diverse ownership structure, including 106 institutional owners and shareholders holding 24,819,090 shares as of May 5, 2026. Major institutional shareholders include Wynnefield Capital Inc., Legion Partners Asset Management, LLC, and BlackRock, Inc. Institutional investors held approximately 66.85% as of January 2025 and around 73.6% as of July 2025. Individual investors held approximately 35% as of November 2024, and insiders increased their holdings to 3.47% in January 2025.